

Joleen T White

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9666502/publications.pdf>

Version: 2024-02-01

21
papers

1,159
citations

567281

15
h-index

677142

22
g-index

22
all docs

22
docs citations

22
times ranked

1328
citing authors

#	ARTICLE	IF	CITATIONS
1	Transthyretin Aggregation under Partially Denaturing Conditions Is a Downhill Polymerization. <i>Biochemistry</i> , 2004, 43, 7365-7381.	2.5	303
2	An Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denatured. <i>Biochemistry</i> , 2001, 40, 11442-11452.	2.5	219
3	D18G Transthyretin Is Monomeric, Aggregation Prone, and Not Detectable in Plasma and Cerebrospinal Fluid: A Prescription for Central Nervous System Amyloidosis. <i>Biochemistry</i> , 2003, 42, 6656-6663.	2.5	117
4	Stability: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team. <i>AAPS Journal</i> , 2014, 16, 392-399.	4.4	58
5	Time-Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 415-427.	2.5	53
6	Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. <i>AAPS Journal</i> , 2016, 18, 1335-1350.	4.4	47
7	Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. <i>Molecular Genetics and Metabolism</i> , 2010, 99, 132-141.	1.1	34
8	Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. <i>Pediatric Research</i> , 2012, 71, 39-45.	2.3	31
9	Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. <i>Molecular Genetics and Metabolism</i> , 2011, 103, 268-274.	1.1	28
10	Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 239-249.	3.5	27
11	R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 57-66.	3.0	22
12	Pharmacokinetics and pharmacodynamics of peginterferon beta1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 514-522.	2.4	20
13	Development, Validation, and Clinical Implementation of an Assay to Measure Total Antibody Response to Naglazyme (Galsulfase). <i>AAPS Journal</i> , 2008, 10, 363-372.	4.4	17
14	Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. <i>Bioanalysis</i> , 2011, 3, 1799-1803.	1.5	16
15	Immunogenicity Risk Assessment for PEGylated Therapeutics. <i>AAPS Journal</i> , 2020, 22, 35.	4.4	13
16	Comparison of Neutralizing Antibody Assays for Receptor Binding and Enzyme Activity of the Enzyme Replacement Therapeutic Naglazyme (Galsulfase). <i>AAPS Journal</i> , 2008, 10, 439-449.	4.4	12
17	Immunogenicity Risk Assessment for Multi-specific Therapeutics. <i>AAPS Journal</i> , 2021, 23, 115.	4.4	10
18	Free and total biotherapeutic evaluation in chromatographic assays: interference from targets and immunogenicity. <i>Bioanalysis</i> , 2012, 4, 2401-2411.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Immunogenicity evaluation strategy for a second-generation therapeutic, PEG-IFN- β -1a. <i>Bioanalysis</i> , 2015, 7, 2801-2811.	1.5	6
20	Incurred sample reproducibility and stability assessment in a cell-based drug concentration assay. <i>Bioanalysis</i> , 2015, 7, 1347-1353.	1.5	2
21	Strategies for method comparison when changes in the immunogenicity method are needed within a clinical program. <i>Bioanalysis</i> , 2020, 12, 431-443.	1.5	2